Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-8-15
pubmed:abstractText
In this national study, we have evaluated a new intensive chemotherapy protocol for adult patients with untreated acute lymphoblastic leukaemia (ALL). One hundred and fifty-three patients with median age 42 years received induction therapy with high-dose cytarabine (Ara-C), cyclophosphamide, daunorubicin, vincristine and betamethasone. A high complete remission (CR) rate (90%) was achieved in patients < 60 years compared with 70% in patients > 60 years (P = 0.004). The estimated 3 year overall survival for all patients was 29% (CI 21-36%) and the estimated continuous complete remission (CCR) at 3 years for the patients achieving CR according to the protocol was 36% (CI 27-45%). A favourable pretreatment characteristic was pre-B phenotype, especially for patients < 40 years without any high-risk factor, with an estimated CCR at 3 years of 62% (CI 41-82%). Stem cell transplantation (SCT) as post-remission therapy, mainly for high-risk patients, gave an estimated 3 year disease free survival (DFS) after SCT of 39% (CI 24-54%). No significant differences in DFS could be found between autologous, related or unrelated donor transplantation. We conclude that this intensive protocol resulted in a high CR rate combined with acceptable side-effects and a favourable CCR for patients with pre-B ALL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-1048
pubmed:author
pubmed:issnType
Print
pubmed:volume
118
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
748-54
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12181041-Adolescent, pubmed-meshheading:12181041-Adult, pubmed-meshheading:12181041-Age Factors, pubmed-meshheading:12181041-Aged, pubmed-meshheading:12181041-Aged, 80 and over, pubmed-meshheading:12181041-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12181041-Cytarabine, pubmed-meshheading:12181041-Disease-Free Survival, pubmed-meshheading:12181041-Drug Administration Schedule, pubmed-meshheading:12181041-Female, pubmed-meshheading:12181041-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:12181041-Humans, pubmed-meshheading:12181041-Immunophenotyping, pubmed-meshheading:12181041-Male, pubmed-meshheading:12181041-Middle Aged, pubmed-meshheading:12181041-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:12181041-Remission Induction, pubmed-meshheading:12181041-Risk Factors, pubmed-meshheading:12181041-Survival Rate
pubmed:year
2002
pubmed:articleTitle
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia.
pubmed:affiliation
The Swedish Adult ALL Group, Uppsala University Hospital, Sweden. helene.hallbook@medicin.uas.lul.se
pubmed:publicationType
Journal Article, Clinical Trial, Multicenter Study